Nasus Pharma Ltd cash flow statement

In fiscal 2025, Nasus Pharma Ltd's operations generated −$4.9m of cash; it spent $14,000 on capital projects, leaving free cash flow of −$4.9m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Nasus Pharma Ltd: cash flow statement, annual
Fiscal year	2025Dec 2025
Cash from operations	−4,918
Stock-based pay	447
Capital spending	14
Free cash flow	−4,932
Free cash flow after stock pay	−5,379
Shares issued	8,485

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: NSRX vs TRLV INDV vs NSRX NSRX vs PBH

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Nasus Pharma Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Nasus Pharma Ltd.